Imidazopyrazines as protein kinase inhibitors

ZHAO, Lianyun, Panduranga Adulla REDDY, Neng-Yang SHIH, Kamil PARUCH, Timothy GUZI and Arshad SIDDIQUI. Imidazopyrazines as protein kinase inhibitors. 2007.

Basic information

• Original name: Imidazopyrazines as protein kinase inhibitors
• Name in Czech: Imidazopyrazines as protein kinase inhibitors
• Authors: ZHAO, Lianyun, Panduranga Adulla REDDY, Neng-Yang SHIH, Kamil PARUCH, Timothy GUZI and Arshad SIDDIQUI.
• Edition: Number: WO 2007/145921 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough, 2007.

Other information

• Original language: English
• Type of outcome: Patent
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Faculty of Science
• Keywords (in Czech): imidazopyrazines; kinase; inhibitor
• Keywords in English: imidazopyrazines; kinase; inhibitor
• Tags: imidazopyrazines, inhibitor, Kinase

Abstract

The invention provides a class of imidazopyrazine compds. of formula I as inhibitors of protein and/or checkpoint kinases, methods of prepg. such compds., pharmaceutical compns. including one or more such compds., methods of prepg. pharmaceutical formulations including one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the protein or checkpoint kinases using such compds. or pharmaceutical compns. Compds. of formula I wherein R is H, halo, amino, (un)substituted alkyl, (un)substituted (hetero)aryl, (un)substituted (hetero)cycloalkyl, etc.; R1 is H, (un)substituted alkyl, (un)substituted (hetero)aryl(alkyl), (un)substituted cycloalkenyl, etc.; R2 and R3 are independently H, halo, amino, (un)substituted alkyl, (un)substituted (hetero)aryl, (un)substituted cycloalkyl, etc.; X is a covalent bond, CONH and derivs., SO2NH and derivs., NHCONH and derivs., CO2, OCO, OCONH and derivs., etc.; R4 is (un)substituted alkyl, (un)substituted CO2-alkyl, (un)substituted heterocyclyl, (un)substituted aryl and amine; and their pharmaceutically acceptable salts, solvates, esters and prodrugs thereof, are claimed. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their protein kinase inhibitory activity (some data given).

Abstract (in Czech)

viz Anotace